{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:11:20Z","timestamp":1788671480632,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006419","name":"EuroQol Research Foundation","doi-asserted-by":"publisher","award":["EQ Project 339-RA"],"award-info":[{"award-number":["EQ Project 339-RA"]}],"id":[{"id":"10.13039\/501100006419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.03.2239","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:28:03Z","timestamp":1776101283000},"page":"1653-1662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validity, Reliability, and Responsiveness of the EQ-5D in Hematological Cancers: A Systematic Review of Measurement Properties"],"prefix":"10.1016","volume":"29","author":[{"given":"Aleksandra","family":"Dudzisz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz W.","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilian","family":"Snarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Golicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2239_bib3","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41375-022-01596-z","article-title":"Changing causes of death in persons with haematological cancers 1975-2016","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2239_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0609.2008.01126.x","article-title":"Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma","volume":"81","author":"Strasser-Weippl","year":"2008","journal-title":"Eur J Haematol"},{"issue":"27","key":"10.1016\/j.jval.2026.03.2239_bib5","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1200\/JCO.2008.20.0634","article-title":"Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients","volume":"27","author":"Courneya","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2239_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2008.07407.x","article-title":"Patients\u2019 experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial","volume":"143","author":"Else","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2239_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","article-title":"Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences","volume":"72","author":"Gulbrandsen","year":"2004","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2239_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2004.00233.x","article-title":"Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr","volume":"72","author":"Holzner","year":"2004","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2239_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.29","article-title":"Haematological cancer and quality of life: a systematic literature review","volume":"5","author":"Allart-Vorelli","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jval.2026.03.2239_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1745017902016010174","article-title":"Health- related quality of life in patients with onco-hematological diseases","volume":"16","author":"La Nasa","year":"2020","journal-title":"Clin Pract Epidemiol Ment Health"},{"issue":"23","key":"10.1016\/j.jval.2026.03.2239_bib11","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.3390\/cancers14236007","article-title":"The reporting, use, and validity of patient-reported outcomes in multiple myeloma in clinical trials: a systematic literature review","volume":"14","author":"Salek","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.jval.2026.03.2239_bib12","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.3390\/cancers15245764","article-title":"Guidelines for the use and reporting of patient-reported outcomes in multiple myeloma clinical trials","volume":"15","author":"Laane","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2239_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2026.03.2239_bib16","series-title":"EuroQol Group Monographs","article-title":"EQ-5D value sets: inventory, comparative review and user guide","author":"Szende","year":"2007"},{"key":"10.1016\/j.jval.2026.03.2239_bib19","first-page":"1","article-title":"COSMIN methodology for systematic reviews of patient-reported outcome measures (PROMs). User manual","volume":"78","author":"Mokkink","year":"2018","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2239_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes","volume":"63","author":"Mokkink","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2239_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","article-title":"The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study","volume":"19","author":"Mokkink","year":"2010","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2239_bib22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","article-title":"COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures","volume":"27","author":"Mokkink","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2026.03.2239_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111422","article-title":"Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024","volume":"173","author":"Elsman","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2026.03.2239_bib24","article-title":"Systematic review of measurement properties of the EQ-5D in hematologic cancers. CRD42024519005","author":"Golicki","year":"2024","journal-title":"Prospero"},{"key":"10.1016\/j.jval.2026.03.2239_bib25","series-title":"Statistical Power Analysis for the Behavioural Science","author":"Cohen","year":"1988"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2239_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2239_bib27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2026.03.2239_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jclinepi.2021.03.015","article-title":"The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L","volume":"137","author":"Gamper","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2239_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","article-title":"Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes","volume":"121","author":"Jansen","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2239_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","article-title":"Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma","volume":"87","author":"Kvam","year":"2011","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40271-016-0190-z","article-title":"EQ-5D health utility scores: data from a comprehensive Canadian Cancer Centre","volume":"10","author":"Naik","year":"2017","journal-title":"Patient"},{"issue":"8","key":"10.1016\/j.jval.2026.03.2239_bib32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jval.2012.08.2201","article-title":"Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer","volume":"15","author":"Rowen","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2239_bib33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11136-020-02644-w","article-title":"A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients","volume":"30","author":"Yu","year":"2021","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13561-024-00560-0","article-title":"A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances","volume":"14","author":"Cao","year":"2024","journal-title":"Health Econ Rev"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12955-020-01341-z","article-title":"Validation of the Chinese EORTC chronic lymphocytic leukaemia module - application of classical test theory and item response theory","volume":"18","author":"Dong","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41687-020-0185-3","article-title":"Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed\/refractory mantle cell lymphoma, and comparison to EQ-5D-5L","volume":"4","author":"Herdman","year":"2020","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12955-024-02297-0","article-title":"EQ-5D-5L and SF-6Dv2 health utilities scores of diffuse large B-cell lymphoma patients in China","volume":"22","author":"Li","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"15","key":"10.1016\/j.jval.2026.03.2239_bib38","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1002\/cncr.32977","article-title":"Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy","volume":"126","author":"Peipert","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2239_bib39","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.31557\/APJCP.2022.23.9.3167","article-title":"Psychometric properties of MD Anderson symptoms inventory for acute myeloid leukemia patients in Thailand","volume":"23","author":"Rattanathammethee","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2239_bib40","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jval.2016.05.008","article-title":"Which questionnaire should be used to measure quality-of-life utilities in patients with acute leukemia? An evaluation of the validity and interpretability of the EQ-5D-5L and preference-based questionnaires derived from the EORTC QLQ-C30","volume":"19","author":"van Dongen-Leunis","year":"2016","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2239_bib41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10198-024-01730-x","article-title":"Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin\u2019s lymphoma","volume":"26","author":"Xu","year":"2025","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2239_bib42","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10198-024-01672-4","article-title":"Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China","volume":"25","author":"Zhang","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2239_bib43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10198-025-01815-1","article-title":"Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients","volume":"27","author":"Zhang","year":"2026","journal-title":"Eur J Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2239_bib44","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.12759","article-title":"Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials","volume":"21","author":"Oladapo","year":"2015","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2239_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14737167.2016.1146594","article-title":"Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments","volume":"16","author":"Schwenkglenks","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2239_bib46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.critrevonc.2015.07.012","article-title":"Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned?","volume":"96","author":"Cannella","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jval.2026.03.2239_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.06.006","article-title":"A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia","volume":"70","author":"Bryant","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2239_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40487-016-0039-6","article-title":"Health-related quality of life of patients with acute myeloid leukemia: a systematic literature review","volume":"5","author":"Korol","year":"2017","journal-title":"Oncol Ther"},{"key":"10.1016\/j.jval.2026.03.2239_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/CEOR.S187409","article-title":"Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review","volume":"11","author":"Forsythe","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2239_bib50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-015-0367-7","article-title":"Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature","volume":"34","author":"Frey","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.jval.2026.03.2239_bib51","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1080\/03007995.2018.1474091","article-title":"Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors","volume":"34","author":"Lin","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.jval.2026.03.2239_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.21503","article-title":"Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review","volume":"84","author":"Pinchon","year":"2009","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2239_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.14425","article-title":"Patient-reported outcomes in Phase 3 clinical trials for blood cancers: a systematic review","volume":"7","author":"Patel","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2239_bib54","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jval.2020.04.1825","article-title":"EQ-5D-derived health state utility values in hematologic malignancies: a catalog of 796 utilities based on a systematic review","volume":"23","author":"Golicki","year":"2020","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2239_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.09.237","article-title":"Systematic review of psychometric properties of the EQ-5D questionnaires in patients with hematologic malignant neoplasms","volume":"19","author":"Mlynczak","year":"2016","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2026.03.2239_bib56","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2239_bib57","doi-asserted-by":"crossref","first-page":"A323","DOI":"10.1016\/j.jval.2013.08.007","article-title":"Responsiveness of the EQ-5D in oncology: a meta-analysis","volume":"16","author":"Smith","year":"2013","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152602382X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152602382X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:16:55Z","timestamp":1788668215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152602382X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S109830152602382X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2239","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validity, Reliability, and Responsiveness of the EQ-5D in Hematological Cancers: A Systematic Review of Measurement Properties","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}